New plasma protein C and protein S concentrate: A synergy for therapeutic purposes
Vox Sanguinis · 2024
DOI: 10.1111/vox.13567 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vox Sanguinis, 2024. Verfasst von Filippo Mori und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research and Innovation, Kedrion Biopharma, Bolognana, Italy. Hauptthemen laut MEDLINE: Purpura Fulminans, Protein C Deficiency. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kedrion Biopharma Inc.
Abstract (Originalsprache)
Background and Objectives Deficiencies of protein C (PC) or protein S (PS) are rare diseases, characterized by mutations in the PC or PS genes, which encode plasma serine proteases with anti‐coagulant activity. Severe PC or PS deficiencies manifest in early life as neonatal purpura fulminans, a life‐threatening heamorrhagic condition requiring immediate treatment. First‐line treatment involves replacement therapy, followed by maintenance with anti‐coagulants. Replacement therapy with specific protein concentrates is currently only limited to PC, and therefore, a PC + PS concentrate represents a useful addition to therapeutic options, particularly for severe PS deficiency. Further, the production of a PC + PS concentrate from unused plasma fractionation intermediates would impact favourably on manufacturing costs, and consequently therapy prices for patients and health systems. Materials and Methods Several chromatographic runs were performed on the same unused plasma fractionation intermediates using different supports to obtain a PC/PS concentrate. The best chromatographic mediums were chosen, in terms of specific activity and recovery. A full process of purification including virus inactivation/removal and lyophilization steps was set up.
Results
The final freeze‐dried product had a mean PC concentration of 47.75 IU/mL with 11% of PS, and a mean specific activity of 202.5 IU/mg protein, corresponding to over 12,000‐fold purification from plasma.
Conclusion
The development of a novel concentrated PC/PS mixture obtained from a waste fraction of other commercial products could be used for its potential therapeutic role in the management of neonatal purpura fulminans pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Research and Innovation, Kedrion Biopharma, Bolognana, Italy.
ORCID-Profile: Filippo Mori
Förderung
- Kedrion Biopharma Inc
Zitieren
APA
Mori, F., Angelini, C., & Farina, C. (2024). New plasma protein C and protein S concentrate: A synergy for therapeutic purposes. Vox Sanguinis. https://doi.org/10.1111/vox.13567
Vancouver
Mori F, Angelini C, Farina C. New plasma protein C and protein S concentrate: A synergy for therapeutic purposes. Vox Sanguinis. 2024. doi:10.1111/vox.13567
BibTeX
@article{Mori2024,
author = {Mori, Filippo and Angelini, Cristina and Farina, Claudio},
title = {New plasma protein C and protein S concentrate: A synergy for therapeutic purposes},
journal = {Vox Sanguinis},
year = {2024},
doi = {10.1111/vox.13567}
}
EUVIMED